^
    Back
    Association details:
    Biomarker:ALK R214H
    Cancer:Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Mayo Clinic Proceedings
    Title:

    Complete Response of Anaplastic Lymphoma Kinase–Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib

    Excerpt:
    A 29-year-old woman had ENKTL initially diagnosed...next-generation sequencing identified a mutation in the ALK gene (ALK R214H). Bronchoscopy performed on day 7 of crizotinib therapy revealed an improved airway without gross tumor.
    DOI:
    10.1016/j.mayocp.2016.06.014